Compounding Pharmacy Peptide Production Allowed by Policy
Compounding pharmacies can now legally produce six specific peptides previously restricted by federal safety regulations.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Do you support the production of wellness products that have not completed rigorous FDA clinical trials?
The Trump administration has issued an interim policy halting enforcement against compounding pharmacies producing six specific peptides, including BPC-157 and Semax. This shift reverses a 2023 FDA ruling that prohibited their production, marking a significant regulatory change for compounding businesses.
Why it matters
The change allows pharmacies to resume compounding products used for muscle recovery, weight loss, and sleep improvement that were previously blocked by safety-related bans. It stems from a broader effort led by Robert F. Kennedy Jr. to legalize 14 total peptides, signaling a shift in FDA enforcement priorities.
The government is now allowing the production of six specific peptides previously barred under 2023 regulations. The market impact was immediate, with Hims & Hers Health stock price rising 2.8% following the announcement.
The players
Robert F. Kennedy Jr.
An official leading the initiative to legalize the production of 14 specific peptides.
Hims & Hers Health
A direct-to-consumer health and wellness company that saw its stock price rise 2.8%.
FDA
The federal regulatory agency responsible for overseeing pharmacy safety and drug approvals.
The details
The Office of Management and Budget implemented the interim policy after an FDA advisory committee voted in July 2026 to reclassify these compounds. While FDA staff had recommended against the change, the administration restructured the committee to include industry-affiliated experts. Pharmacies may now produce BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, despite none being formally FDA-approved for clinical use.
Timeline
2023: FDA bans the compounding of certain peptides.
July 2026: FDA advisory committee votes on peptide reclassification.
October 2026: Administration issues interim policy allowing production of six peptides.
February 2027: Next FDA advisory committee meeting scheduled.
Market Landscape
The new policy represents a stark reversal of the 2023 FDA ruling that initially banned the compounding of these products. It departs from the agency's previous focus on safety-driven restrictions, aligning instead with a new administrative push to expand market access for peptide therapies.
Compounding pharmacies should monitor the list of approved substances to ensure compliance as the formal reclassification process continues. Operators should consult with legal counsel to assess how this interim policy affects local production capabilities and risk exposure until a final ruling is issued.
The takeaway
The interim policy provides a new operational window for pharmacies to produce previously banned substances while the formal regulatory process remains in flux. Monitor the February 2027 committee meeting to track whether the permitted status of these six peptides becomes permanent or remains subject to future revocation.
What happens next
The FDA is expected to host a follow-up advisory committee meeting in February 2027 to continue the reclassification review process for these products.
Further reading
Operators can find additional updates in our Healthcare section.
Live Poll
Do you support the production of wellness products that have not completed rigorous FDA clinical trials?
